MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-05-2026
DENTSPLY SIRONA Gross Profit 2011-2026 | XRAY
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit DENTSPLY SIRONA
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.84 B | 1.96 B | 2.09 B | 2.13 B | 2.35 B | 1.66 B | 2.16 B | 2.07 B | 2.19 B | 2 B | 1.52 B | 1.6 B | 1.58 B | 1.56 B | 1.27 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.35 B | 1.27 B | 1.86 B |
Quarterly Gross Profit DENTSPLY SIRONA
| 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 427 M | - | 441 M | 490 M | 466 M | - | 495 M | 511 M | 506 M | - | 495 M | 550 M | 519 M | - | 508 M | 581 M | 521 M | - | 569 M | 595 M | 579 M | - | 442 M | 176 M | 468 M | 611 M | 514 M | 541 M | 500 M | 525 M | 476 M | 553 M | 514 M | 593 M | 559 M | 544 M | 492 M | 542 M | 514 M | 527 M | 419 M | 375 M | 369 M | 400 M | 373 M | 393 M | 388 M | 424 M | 394 M | 398 M | 376 M | 415 M | 388 M | - | 364 M | 407 M | 393 M | - | 298 M | 315 M | 300 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 611 M | 176 M | 463 M |
Gross Profit of other stocks in the Medical instruments industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Atrion Corporation
ATRI
|
62.4 K | - | - | $ 810 M |  USA |
 |
The Cooper Companies
COO
|
2.68 B | $ 67.42 | 8.71 % | $ 13.4 B | USA |
 |
Glaukos Corporation
GKOS
|
283 M | $ 125.33 | 2.91 % | $ 7.17 B | USA |
 |
Luminex Corporation
LMNX
|
248 M | - | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
479 K | - | -9.52 % | $ 20.6 M | USA |
 |
Intuitive Surgical
ISRG
|
6.64 B | $ 420.81 | 0.48 % | $ 150 B | USA |
 |
Alcon
ALC
|
5.74 B | $ 66.66 | 0.15 % | $ 40.4 B |  Schweiz |
 |
ICU Medical
ICUI
|
822 M | $ 135.84 | 0.67 % | $ 3.35 B | USA |
 |
iRhythm Technologies
IRTC
|
527 M | $ 107.78 | 0.4 % | $ 3.45 B | USA |
 |
Repro Med Systems
KRMD
|
25.6 M | $ 3.97 | -4.23 % | $ 183 M | USA |
 |
LeMaitre Vascular
LMAT
|
179 M | $ 94.15 | 0.63 % | $ 2.13 B | USA |
 |
Masimo Corporation
MASI
|
1 B | $ 178.91 | 0.01 % | $ 9.54 B | USA |
 |
Antares Pharma, Inc.
ATRS
|
86.5 M | - | - | $ 955 M | USA |
 |
Cantel Medical Corp.
CMD
|
436 M | - | -1.18 % | $ 3.4 B | USA |
 |
CRH Medical Corporation
CRHM
|
1.68 M | - | - | $ 282 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
1.48 B | - | -0.05 % | $ 10.3 B | USA |
 |
Microbot Medical
MBOT
|
117 K | $ 1.85 | -5.62 % | $ 84.7 M |  Israel |
 |
Ekso Bionics Holdings
EKSO
|
6.84 M | - | - | $ 28.6 M | USA |
 |
Milestone Scientific
MLSS
|
6.41 M | $ 0.4 | -8.43 % | $ 32.8 M | USA |
 |
Varian Medical Systems, Inc.
VAR
|
1.38 B | - | -0.02 % | $ 16.3 B | USA |
 |
electroCore
ECOR
|
27.8 M | $ 8.55 | -13.98 % | $ 72.5 K | USA |
 |
Envista Holdings Corporation
NVST
|
1.49 B | $ 23.06 | 0.85 % | $ 3.87 B | USA |
 |
Haemonetics Corporation
HAE
|
788 M | $ 71.1 | 1.83 % | $ 3.35 B | USA |
 |
STERIS plc
STE
|
2.63 B | $ 211.73 | -0.26 % | $ 20.8 B | USA |
 |
Isoray
ISR
|
1.43 M | - | 0.03 % | $ 108 M | USA |
 |
STAAR Surgical Company
STAA
|
182 M | $ 29.64 | -0.74 % | $ 1.47 B | USA |
 |
InfuSystem Holdings
INFU
|
80.3 M | $ 9.27 | 1.31 % | $ 191 M | USA |
 |
Teleflex Incorporated
TFX
|
307 M | $ 129.84 | -1.69 % | $ 5.79 B | USA |
 |
Utah Medical Products
UTMD
|
5.26 M | $ 68.85 | 1.26 % | $ 223 M | USA |
 |
Merit Medical Systems
MMSI
|
738 M | $ 64.16 | 1.78 % | $ 3.8 B | USA |
 |
West Pharmaceutical Services
WST
|
1.1 B | $ 315.05 | -0.7 % | $ 22.8 B | USA |
 |
Retractable Technologies
RVP
|
47 K | $ 0.67 | 1.52 % | $ 20.1 M | USA |
 |
Pro-Dex
PDEX
|
19.5 M | $ 66.06 | -1.4 % | $ 217 M | USA |
 |
Predictive Oncology
POAI
|
6.53 K | - | - | $ 31.1 M | USA |
 |
BioLife Solutions
BLFS
|
62.1 M | $ 26.89 | -0.74 % | $ 1.28 B | USA |
 |
Stereotaxis
STXS
|
17.1 M | $ 1.79 | -4.8 % | $ 163 M | USA |
 |
Baxter International
BAX
|
3.38 B | $ 19.45 | 0.52 % | $ 9.98 B | USA |
 |
ResMed
RMD
|
2.02 B | $ 195.14 | 0.43 % | $ 28.5 B | USA |
 |
AtriCure
ATRC
|
401 M | $ 26.83 | -1.61 % | $ 1.28 B | USA |
 |
Harvard Bioscience
HBIO
|
49.9 M | $ 6.1 | -5.86 % | $ 271 M | USA |
 |
NeuroMetrix
NURO
|
1.68 M | - | 5.05 % | $ 9.02 M | USA |
 |
AngioDynamics
ANGO
|
158 M | $ 11.98 | -0.42 % | $ 489 M | USA |
 |
Becton, Dickinson and Company
BDX
|
8.29 B | $ 151.64 | 1.45 % | $ 43.6 B | USA |
 |
Nephros
NEPH
|
11.6 M | $ 3.38 | -5.85 % | $ 35.9 M | USA |
 |
OraSure Technologies
OSUR
|
48.2 M | $ 4.05 | -3.0 % | $ 298 M | USA |
 |
Repligen Corporation
RGEN
|
151 M | $ 122.76 | -2.99 % | $ 6.9 M | USA |